[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631097":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":28,"armGroups":29,"interventions":24,"overallOfficials":36,"centralContacts":41,"locations":46,"responsibleParty":155,"collaborators":157,"id":173,"slug":24,"hasResults":174,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":24,"eligibilityCriteria":178,"healthyVolunteers":174,"sex":179,"minAge":180,"maxAge":24,"enrollmentInfo":181,"targetDuration":24,"studyType":184,"phases":24,"briefSummary":185,"conditions":186,"keywords":24,"overallStatus":89,"whyStopped":24,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":24,"otherOutcomes":24},[9,13,16,20],{"measure":10,"description":11,"timeFrame":12},"Levels of circulating tumor DNA (ctDNA)","Quantification of circulating tumor DNA levels in peripheral blood samples to evaluate their association with the clinical course of the disease (stable disease, spontaneous regression, or progression according to RECIST criteria).","Baseline and every 3 months during the first year, then every 6 months up to 36 months.",{"measure":14,"description":15,"timeFrame":12},"Phenotypic profile of circulating immune cells","Characterization of circulating immune cell subsets in peripheral blood samples using immunophenotyping assays.",{"measure":17,"description":18,"timeFrame":19},"Tumor immune microenvironment characteristics","Assessment of immune cell infiltration and inflammatory markers in available tumor biopsy samples to characterize the tumor immune microenvironment.","Baseline.",{"measure":21,"description":22,"timeFrame":23},"Clinical disease course","Clinical disease course assessed as stable disease, spontaneous regression, or progression according to RECIST criteria.","From baseline up to 36 months.",null,{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":26,"timePerspective":27,"maskingInfo":24},"COHORT","PROSPECTIVE","* Patients with primary sporadic desmoid-type fibromatosis with measurable disease under active surveillance\n* Patients with primary sporadic desmoid-type fibromatosis with measurable disease receiving systemic treatment.",[30,33],{"label":31,"type":24,"description":32,"interventionNames":24},"Patients under active surveillance","Patients with primary sporadic desmoid-type fibromatosis with measurable disease",{"label":34,"type":24,"description":35,"interventionNames":24},"Patients receiving systemic treatment","Patients with primary sporadic desmoid-type fibromatosis with measurable disease.",[37],{"name":38,"affiliation":39,"role":40},"Chiara Colombo, MD, Surgical Oncologist","Fondazione IRCCS Istituto Nazionale dei Tumori di Milano","PRINCIPAL_INVESTIGATOR",[42],{"name":38,"role":43,"phone":44,"phoneExt":24,"email":45},"CONTACT","+390223902740","chiara.colombo@istitutotumori.mi.it",[47,64,77,87,101,114,127,140],{"facility":48,"status":49,"city":50,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"IRCCS Istituto di Candiolo Fondazione del Piemonte per l'Oncologia","NOT_YET_RECRUITING","Candiolo","Italy","IT",{"type":54,"coordinates":55},"Point",[56,57],7.59812,44.95858,{"lat":57,"lon":56},[60,63],{"name":61,"role":43,"phone":24,"phoneExt":24,"email":62},"Giovanni Grignani, MD","giovanni.grignani@ircc.it",{"name":61,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":65,"status":49,"city":66,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Azienda Ospedaliero Universitaria Careggi","Florence",{"type":54,"coordinates":68},[69,70],11.24626,43.77925,{"lat":70,"lon":69},[73,76],{"name":74,"role":43,"phone":24,"phoneExt":24,"email":75},"Domenico Campanacci, MD","domenicoandrea.campanacci@unifi.it",{"name":74,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":78,"status":49,"city":66,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":79,"geoPoint":81,"contacts":82},"Azienda Usl Toscana centro",{"type":54,"coordinates":80},[69,70],{"lat":70,"lon":69},[83,86],{"name":84,"role":43,"phone":24,"phoneExt":24,"email":85},"Giacomo Baldi, MD","giacomogiulio.baldi@uslcentro.toscana.it",{"name":84,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":88,"status":89,"city":90,"state":24,"zip":91,"country":51,"countryCode":52,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Fondazione IRCCS Istituto Nazionale dei Tumori","RECRUITING","Milan","20133",{"type":54,"coordinates":93},[94,95],9.18951,45.46427,{"lat":95,"lon":94},[98,100],{"name":99,"role":43,"phone":44,"phoneExt":24,"email":45},"Colombo Chiara, MD, Surgical oncologst",{"name":38,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":102,"status":49,"city":103,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"IRCCS Istituto Oncologico Veneto IOV","Padova",{"type":54,"coordinates":105},[106,107],11.14261,44.38225,{"lat":107,"lon":106},[110,113],{"name":111,"role":43,"phone":24,"phoneExt":24,"email":112},"Antonella Brunello, MD","antonella.brunello@iov.veneto.it",{"name":111,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":115,"status":49,"city":116,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Azienda Ospedaliera Universitaria Policlinico \"Paolo Giaccone\"","Palermo",{"type":54,"coordinates":118},[119,120],13.3636,38.1166,{"lat":120,"lon":119},[123,126],{"name":124,"role":43,"phone":24,"phoneExt":24,"email":125},"Giuseppe Badalamenti, MD","giuseppe.badalamenti@unipa.it",{"name":124,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":128,"status":49,"city":129,"state":24,"zip":24,"country":51,"countryCode":52,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Università Campus Bio-Medico","Rome",{"type":54,"coordinates":131},[132,133],12.51133,41.89193,{"lat":133,"lon":132},[136,139],{"name":137,"role":43,"phone":24,"phoneExt":24,"email":138},"Bruno Vincenzi, MD","B.Vincenzi@policlinicocampus.it",{"name":137,"role":40,"phone":24,"phoneExt":24,"email":24},{"facility":141,"status":49,"city":142,"state":24,"zip":24,"country":143,"countryCode":144,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Erasmus University Medical Centre","Rotterdam","Netherlands","NL",{"type":54,"coordinates":146},[147,148],4.47917,51.9225,{"lat":148,"lon":147},[151,154],{"name":152,"role":43,"phone":24,"phoneExt":24,"email":153},"Stefanie Hakkesteegt, MD","s.hakkesteegt@erasmusmc.nl",{"name":152,"role":40,"phone":24,"phoneExt":24,"email":24},{"type":156,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[158,161,163,165,167,169,171],{"name":159,"class":160},"Campus Biomedico - Roma","UNKNOWN",{"name":162,"class":6},"Candiolo Cancer Institute - IRCCS",{"name":164,"class":6},"Azienda Ospedaliero-Universitaria Careggi",{"name":166,"class":6},"Azienda USL Toscana Centro",{"name":168,"class":6},"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo",{"name":170,"class":6},"Erasmus University Rotterdam",{"name":172,"class":6},"Istituto Oncologico Veneto IRCCS","100631097",false,"NCT07496242","Immunological Phenotype of Desmoid-fibromatosis-affected Patients.","Immunological Profile of Patients With Desmoid-type Fibromatosis Under Active Surveillance.","Inclusion Criteria:\n\n* Patients with primary sporadic desmoid-type fibromatosis with measurable disease under active surveillance\n* Patients with primary sporadic desmoid-type fibromatosis with measurable disease receiving systemic treatment.","ALL","18 Years",{"count":182,"type":183},200,"ESTIMATED","OBSERVATIONAL","This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.",[187],"Desmoid-Type Fibromatosis","2026-03-23",{"date":190,"type":191},"2026-03-27","ACTUAL",{"date":193,"type":191},"2025-05-27",{"date":195,"type":183},"2026-12",{"name":5,"class":6},8]